AbbVie Inc. $ABBV Position Lifted by Cooper Financial Group

Cooper Financial Group raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 23.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 14,096 shares of the company’s stock after acquiring an additional 2,636 shares during the quarter. Cooper Financial Group’s holdings in AbbVie were worth $3,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Corient Private Wealth LP purchased a new position in AbbVie during the second quarter valued at $559,736,000. Legal & General Group Plc purchased a new stake in AbbVie in the second quarter worth about $2,905,952,000. Jupiter Topco LLC bought a new position in shares of AbbVie in the second quarter worth about $1,560,354,000. Cardano Risk Management B.V. raised its stake in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the period. Finally, Diamant Asset Management Inc. lifted its position in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 1.8%

NYSE ABBV traded up $4.67 during trading hours on Wednesday, reaching $271.37. The company’s stock had a trading volume of 6,075,433 shares, compared to its average volume of 6,434,720. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94. The company has a market capitalization of $479.44 billion, a price-to-earnings ratio of 76.66, a PEG ratio of 1.20 and a beta of 0.24. The firm’s 50-day moving average price is $258.27 and its 200-day moving average price is $235.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ABBV. Scotiabank increased their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a report on Tuesday. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Leerink Partners increased their price objective on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley raised their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $274.32.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations for AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review for the antibody-drug conjugate, strengthening AbbVie’s growing oncology pipeline. Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
• Positive Sentiment: AbbVie and Genmab reported that the Epkinly (epcoritamab) plus R-CHOP combination reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 success supports potential expansion into frontline treatment and could improve the long-term commercial outlook for the partnership. AbbVie Cut Frontline DLBCL Progression Or Death Risk By 51%
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, adding to bullish analyst sentiment around the company’s pipeline and earnings potential. AbbVie Stock Price Target Raised at Scotiabank
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may remain focused on whether upcoming results and management commentary support the current premium valuation and forward growth expectations. Should You Buy AbbVie Stock Before Oct. 30?
• Negative Sentiment: AbbVie updated third-quarter 2026 EPS guidance to $3.73-$3.77, below the roughly $3.85 consensus estimate. The lower outlook may limit near-term upside and suggests investors will scrutinize operating performance despite the positive drug-development news. AbbVie Issues Q3 2026 Earnings Guidance
• Negative Sentiment: One report highlighted AbbVie’s payout ratio of about 190%, raising concerns that the dividend currently exceeds reported earnings and could face pressure if cash flow weakens. This is a longer-term risk rather than a direct change to the dividend policy. AbbVie Pays Out More Than It Earns

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.